Category Archives: EP and UK Practice

Regeneron v. Kymab – “Sufficiency” and Enablement in the U.K.

Guest post from Paul Cole. Regeneron Pharmaceuticals Inc v Kymab Ltd. [2020] UKSC 27 related to infringement of EP-B-1,360,287 and its divisional EP-B-2264123. The 287 parent related to a method of modifying an endogenous immunoglobulin variable region gene locus in … Continue reading

Posted in EP and UK Practice | Tagged | Leave a comment

EPO – New Guidance On Added Subject Matter

A guest post from Paul Cole. Readers will be aware that added subject matter issues have for a long time been a thorny issue for EPO Examination practice. On 7 February 2014 a symposium on EPO practice regarding Art. 123(2) … Continue reading

Posted in EP and UK Practice | Tagged , , , , , | Leave a comment

Australia: Cancer Voices v Myriad Opinion Affirmed

This is a guest post from Paul Cole. An opinion was handed down earlier today by the Federal Court of Australia – Full Court (Allsop C.J., Downsett, Kenny, Bennett and Middleton J.J., D’Arcy v Myriad Genetics Inc [2014] FCAFC 115 … Continue reading

Posted in EP and UK Practice | Tagged , , , , , , , , | 2 Comments

EPO Abolishes Prior “Short” Divisional Guidelines

This is a guest post from Mewburn Ellis of London. The Administrative Council (the governing body of the European Patent Office) has decided at its meeting on 16 October 2013 to change the regulations regarding the deadline for filing divisional … Continue reading

Posted in EP and UK Practice | Tagged , , , , , , | Leave a comment